WGO heads into the back half of July with a striking contradiction at its core: short interest has climbed 44% in a single month while the stock itself has rallied nearly 5% on the week.
The short-side buildup is the dominant story right now. Short interest hit 11.4% of the free float as of July 21 — up from roughly 7.9% just 30 days ago. That month-on-month jump of 44% is sharp for any stock, let alone one in a modest recovery. The daily series tells the story clearly: shorts were running near 2.2–2.4 million shares through most of June, then broke higher around July 10, jumping to 3.1 million shares and holding above 3.2 million since. The ORTEX short score is running at 57.7, elevated but not extreme, and has been grinding higher since early July. Despite the building short position, the borrow market remains relaxed. Availability is at 352%, meaning there are more than three shares available to lend for every one already borrowed — well within the normal range and down only slightly on the week. Cost to borrow is a trivial 0.49%, easing from 0.78% at the start of July. There is no squeeze pressure in the lending market; shorts are adding exposure cheaply and with room to grow.
Options positioning adds a secondary note of caution. The put/call ratio edged up to 0.49, roughly 1.5 standard deviations above its 20-day average of 0.41. That's not an alarm signal on its own — the 52-week high PCR is 1.59, so the current reading is nowhere near historic extremes — but it does suggest options traders have become modestly more defensive over the past week, shifting gently in the same direction as the shorts.
The Street narrative explains why bears are gaining confidence. Analysts have been cutting targets with notable consistency since late June. Truist's Patrick Scholes trimmed his buy-rated target from $43 to $35 on July 8. BMO slashed from $48 to $38 while keeping an Outperform. Benchmark dropped from $48 to $40. Even Roth Capital, holding Neutral, cut to $32 from $38. The mean price target has drifted to $38 — a 25% premium to the $30.38 close, which on paper looks generous, but the direction of travel is relentlessly lower. Citigroup, which downgraded to Neutral in late May from Buy with a target cut from $46 to $30, then nudged back to $30 just last week — a minor move that underscores the lack of bullish conviction. The bull case rests on towable segment strength and dealer readiness for a demand recovery in the second half of fiscal 2026. The bear case is more immediate: weak retail conditions, channel imbalances, and a stock that, at roughly 14x trailing earnings and under 0.75x book, is cheap for a reason. EPS momentum is negative on both 30-day and 90-day views, ranking near the bottom of the universe at the 3rd and 8th percentiles respectively. The 12-month forward EPS growth rank sits at just 13. Value scores look reasonable — EV/EBITDA near 9.2x — but that multiple has expanded 1.1 turns over the past 30 days, meaning the stock has de-rated on earnings, not re-rated on recovery.
Institutional flows add one genuinely interesting data point. Pzena Investment Management added 716,000 shares in the most recent reported quarter to hold 6% of the company — a meaningful addition from a deep-value manager that suggests at least one patient buyer sees the valuation floor as real. BlackRock added modestly too. Against that, the short community is clearly voting the other way, at least for now.
The next scheduled earnings event is October 22. After the June 25 print the stock jumped nearly 15% in a single day — a reminder that Q3 2026 results against a low base carry meaningful event risk in either direction. Between now and then, the key tension to watch is whether short interest continues its July climb or flattens out as the stock consolidates near $30 — the level where Citigroup's Neutral sits and where the borrow market suggests shorts still have room to press.
See the live data behind this article on ORTEX.
Open WGO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
